Botanicals, vitamins, and minerals and the liver: Therapeutic applications and potential toxicities

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 25, Issue 7, 2003, Pages 514-524

  Flatland, Bente ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIRSIUM; SILYBUM;

EID: 0041736395     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Massey PB: Dietary supplements. Med Clin North Am 86:127-147, 2002.
2. Taillon C, Andreasen A: Veterinary nutraceutical medicine. Can Vet J 41:231-234, 2000.
3. Hare D: Complementary and alternative veterinary medicine. Can Vet J 40:376-377, 1999.
4. Nolen RS: Facing crackdown, dietary supplement companies promise change. JAVMA 221:479-483, 2002.
5. Boothe DM: Nurraceuticals in veterinary medicine: Part I: Definitions and regulations. Compend Contin Educ Pract Vet 19:1248-1255, 1997.
6. Dzanis DA: Nutraceuticals in veterinary medicine. Aust Vet J 77:238-239, 1999.
7. th Annu ACVIM Forum:586-588, 2001.
8. th Annu ACVIM Forum:169-171, 2002.
9. Boothe DM: Nutraceuticals in veterinary medicine: Part II: Safety and efficacy. Compend Contin Educ Pract Vet 20:15-21, 1998.
10. Gross KL, Wedekind KJ, Cowell CS, et al: Nutrients, in Hand MS, Thatcher CD, Remillard RL, et al (eds): Small Animal Clinical Nutrition, ed 4. Topeka, KS, Mark Morris Institute, 2000, pp 21-107.
11. Sokol RJ: Antioxidant defenses in metal-induced liver damage. Semin Liver Dis 16:39-46, 1996.
12. th Annu ACVIM Forum:13-16, 2001.
13. Bulger EM, Helron WS: Nutrient antioxidants in gastrointestinal diseases. Gastroenterol Clin North Am 27:403-419, 1998.
14. Meyers DG, Maloley PA, Weeks D: Safety of antioxidant vitamins. Arch Intern Med 156:925-935, 1996.
15. th ACVIM Technician Progr.60-63, 2001.
16. th Annu ACVIM Forum:26-28, 2002.
17. th Annu ACVIM Forum:538-540, 2002.
18. Matthai J: Vitamin E updated. Indian J Pediatr 63:242-253, 1996.
19. Parks E, Traber MG: Mechanisms of vitamin E regulation: Research over the past decade and focus on the future. Antioxid Redox Signal 2:405-412, 2000.
20. Sokol RJ, Twedt DC, McKim Jr JM, et al: Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology 107:1788-1798, 1994.
21. Twedt DC, Sokol RJ, Devereaux MW, Gumprich E: Vitamin E protects against oxidative damage of bile acids in isolated hepatocytes [abstract]. J Vet Intern Med 12:215, 1998.
22. th Annu ACVIM Forum.610-612, 2001.
23. Brewer GJ, Dick RD, Schall W, et al: Use of zinc acetate to treat copper toxicosis in dogs. JAVMA 201:564-568, 1992.
24. Product information: Denosyl SD4. Edgewood, MD, Nutramax Laboratories, 2001 [package insert].
25. Roudebush P, Davenport DJ, Dimski DS: Hepatobiliary disease, in Hand MS, Thatcher CD, Remillard RL, et al (eds): Small Animal Clinical Nutrition, ed 4. Topeka, KS, Mark Morris Institute, 2000, pp 811-847.
26. Hubbard BS, Vulgamott JC: Feline hepatic lipidosis. Compend Contin Educ Pract Vet 14:459-464, 1992.
27. Cornelius LM, Jacobs G: Feline hepatic lipidosis, in Kirk RW (ed): Current Veterinary Therapy X. Philadelphia, WB Saunders, 1989, pp 869-873.
28. th Annu ACVIM Forum:775-777, 2001.
29. Roudebush P, Sousa CA, Logas DE: Skin and hair disorders, in Hand MS, Thatcher CD, Remillard RL, et al (eds): Small Animal Clinical Nutrition, ed 4. Topeka, KS, Mark Morris Institute, 2000, pp 455-476.
30. Friedel HA, Goa KL, Benfield P: S-Adenosyl-L-methionine: A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 38:389-416, 1989.
31. th Annu ACVIM Forum: 550-552, 2000.
32. Rambaldi A, Gluud C: S-Adenosyl-L-methionine for alcoholic liver disease. Cochrane Database Syst Rev (4):CD002235, 2001.
33. S-Adenosyl-L-methionine (SAMe), in Hendler SS, Rorvik D (eds): PDR for Nutritional Supplements, Montvale, NJ, Medical Economics Co., 2001, pp 410-414.
34. Center SA, Warner K: Hepatic glutathione concentrations in dogs and cats with spontaneous liver disease [abstract]. J Vet Igntern Med 14:381, 2000.
35. Almasio P, Bortolini M, Pagliaro L, et al: Role of S-adenosyl-Lmethionine in the treatment of intrahepatic cholestasis. Drugs 40(suppl 3):111-123, 1990.
36. Coltorti M, Bortolini M, Di Padova C: A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find Exp Clin Pharmacol 12:69-78, 1990.
37. Boothe DM, Center SA, Goul D, et al: New approaches to managing hepatic dysfunction, Part I. Vet Forum:40-45, 2000.
38. Boothe DM, Center SA, Goul D, et al: New approaches to managing hepatic dysfunction, Part II. Vet Forum:44-49, 2000.
39. Center SA, Randolf JF, Warner K, Hoffmann WE: Influence of SAMe on erythrocytes and liver tissue in healthy cats [abstract]. J Vet Intern Med 14:357, 2000.
40. Center SA, Warner K, Hoffman WE, et al: Influence of S-adenosylmethionine (SAMe) on metabolic and morphologic hepatocellular features induced by chronic glucocorticoid administration in dogs [abstract]. J Vet Intern Med 13:253, 1999.
41. Wallace KP, Center SA, Hickford FH, et al: S-Adenosyl-L-methionine (SAMe) for the treatment of acetaminophen toxicity in a dog. JAAHA 38:246-254, 2002.
42. Flora K, Hahn M, Rosen H, et al: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139-143, 1998.
43. Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs 61(14):2035-2063, 2001.
44. Wellington K, Jarvis B: Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 15:465-489, 2001.
45. Luper S: A review of plants used in the treatment of liver disease: Part one. Alternative Med Rev 3:410-421, 1998.
46. Desplaces A, Choppin J, Vogel G, Trost W: The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 25:89-96, 1975.
47. Floersheim GL, Eberhard M, Tschumi P, Duckert F: Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol Appl Pharmacol 46:455-462, 1978.
48. Vogel G, Tuchweber B, Trost W, Mengs U: Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 73:355-362, 1984.
49. Martin R, Wittwer F, Thibaut J, et al: Hepatic regenerative drugs in dogs: Effect of choline and silibinin in dogs with liver damage. Vet Med Small Anim Clin 79:504-510, 1984.
50. Paulova J, Dvorak M, Kolouch F, et al: Evaluation of the hepatoprotective and therapeutic effects of silymarin in liver damage experimentally produced with carbon tetrachloride in dogs. Vet Med (Praha) 35(10):629-635, 1990.
51. Schossler DR, Schossler JE, da Silva CF: Clinical and enzymatic evaluation of dogs with acute toxic hepatitis treated with silymarin. Rev Bras Cien Vet 5:104-109, 1998.
52. Carroll MC, Cote E: Carnitine: A review. Compend Contin Educ Pract Vet 23:45-51, 2001.
53. Center SA: Hepatic lipidosis, glucocorticoid hepatopathy, vacuolar hepatopathy, storage disorders, amyloidosis, and iron toxicity, in Guilford WG, Center SA, Strombeck DR, et al (eds): Strombeck's Small Animal Gastroenterology. Philadelphia, WB Saunders, 1996, pp 766-801.
54. th Annu ACVIM Forum:193-196, 1991.
55. Jacobs G, Cornelius LM, Keene B, et al: Comparison of plasma, liver, and skeletal muscle carnitine concentrations in cats with idiopathic hepatic lipidosis and in healthy cats. Am J Vet Res 51:1349-1351, 1990.
56. Dimski DS: Feline hepatic lipidosis. Semin Vet Med Surg 12:28-33, 1997.
57. Center SA, Harte J, Watrous D, et al: The clinical and metabolic effects of rapid weight loss in obese pet cats and the influence of supplemental oral L-carnitine. J Vet Intern Med 14:598-608, 2000.
58. Borum PR: Carnitine. Annu Rev Nutr 3:233-259, 1983.
59. th Annu ACVIM Forum:666-668, 2002.
60. Sudekum M, Poppenga RH, Raju N, Braselton Jr WE: Pennyroyal oil toxicosis in a dog. JAVMA 200:817-818, 1992.
61. Means C: Selected herbal hazards. Vet Clin North Am Small Anim Pract 32:367-382, 2002.
62. Ooms TG, Khan SA, Means C: Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases. JAVMA 218:225-229, 2001.
63. Bischoff K, Guale F: Australian tea tree (Melaleuca alternifolia) oil poisoning in 3 purebred cats. J Vet Diagn Invest 10:208-210, 1998.
64. Chitturi S, Farrell GC: Herbal hepatotoxicity: An expanding but poorly defined problem. J Gastroenterol Hepatol 15(10):1093-1099, 2000.
65. Stickel F, Egerer G, Seitz HK: Hepatoxicity of botanicals. Public Health Nutr 3:113-124, 2000.
66. Brent J: Three new herbal hepatotoxic syndromes. Clin Toxicol 37:715-719, 1999.
67. Nadir A, Agrawai S, King PD, Marshall JB: Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol 91:1436-1438, 1996.
68. Gorey JD, Wahlqvist ML, Boyce NW: Adverse reaction to a Chinese herbal remedy. Med J Aust 157:484-486, 1992.
69. Miller LG: Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158:2200-2211, 1998.
70. Hepatic toxicity possibly associated with kava-containing products - United States, Germany, and Switzerland, 1999-2002. MMWR Morbid Mortal Wkly Rep 51(47):1065-1067, 2002.
71. Favreau JT, Ryu ML, Braunstein G, et al: Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 136:590-595, 2002.
72. Brown SA, Biggerstaff J, Savidge GF: Disseminated intravascular coagulation and hepatocellular necrosis due to clove oil. Blood Coagul Fibrinolysis 3:665-668, 1992.
73. Thompson DC, Constantin-Teodosiu D, Moldeus P: Metabolism and cytotoxicity of eugenol in isolated rat hepatocytes. Chem Biol Interact 77:137-147, 1991.
74. Beuers U, Spengler U, Pape G: Hepatitis after chronic abuse of senna. Lancet 337:372-373, 1991.